Currently, the NCCN guidelines for breast or testicular cancer explicitly propose molecular (ER, PR and HER2) or serological (AFP, β-hCG and LDH) markers as supplements to the TNM stage for a more accurate prognostic assessment 34, 35. This evidence concerns the gene ESR1 and testicular cancer.